IRIS
BARGAGLI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.040
EU - Europa 22.882
AS - Asia 10.659
SA - Sud America 2.197
AF - Africa 301
OC - Oceania 45
Continente sconosciuto - Info sul continente non disponibili 15
AN - Antartide 1
Totale 59.140
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.609
RU - Federazione Russa 5.230
IT - Italia 4.924
SG - Singapore 3.605
GB - Regno Unito 3.578
CN - Cina 3.306
IE - Irlanda 2.988
BR - Brasile 1.863
SE - Svezia 1.374
DE - Germania 1.272
HK - Hong Kong 1.058
FR - Francia 976
UA - Ucraina 786
VN - Vietnam 737
FI - Finlandia 724
KR - Corea 556
IN - India 407
CA - Canada 256
ES - Italia 231
NL - Olanda 181
JP - Giappone 152
BD - Bangladesh 138
PL - Polonia 122
TR - Turchia 114
MX - Messico 112
CZ - Repubblica Ceca 110
AR - Argentina 103
AT - Austria 93
IQ - Iraq 93
CI - Costa d'Avorio 91
ZA - Sudafrica 82
EC - Ecuador 59
BE - Belgio 57
IR - Iran 54
PK - Pakistan 51
UZ - Uzbekistan 48
SA - Arabia Saudita 44
MA - Marocco 40
ID - Indonesia 38
VE - Venezuela 35
AU - Australia 34
AE - Emirati Arabi Uniti 32
CO - Colombia 32
LT - Lituania 31
CL - Cile 27
PH - Filippine 27
CH - Svizzera 26
JO - Giordania 25
PY - Paraguay 24
AZ - Azerbaigian 23
PE - Perù 23
PT - Portogallo 23
EG - Egitto 21
IL - Israele 20
RO - Romania 18
KZ - Kazakistan 17
DK - Danimarca 16
JM - Giamaica 16
BG - Bulgaria 14
GR - Grecia 14
KE - Kenya 14
UY - Uruguay 13
BO - Bolivia 12
EE - Estonia 12
KG - Kirghizistan 12
LV - Lettonia 11
ET - Etiopia 10
LB - Libano 10
NG - Nigeria 10
TN - Tunisia 10
AL - Albania 9
DZ - Algeria 9
EU - Europa 9
HU - Ungheria 9
LK - Sri Lanka 9
OM - Oman 9
PA - Panama 9
GE - Georgia 8
NO - Norvegia 8
CR - Costa Rica 7
LA - Repubblica Popolare Democratica del Laos 7
MK - Macedonia 7
NZ - Nuova Zelanda 7
SN - Senegal 7
TT - Trinidad e Tobago 7
AM - Armenia 6
BY - Bielorussia 6
CY - Cipro 6
DO - Repubblica Dominicana 6
LU - Lussemburgo 6
MY - Malesia 6
NP - Nepal 6
RS - Serbia 6
BB - Barbados 5
GY - Guiana 5
TH - Thailandia 5
TW - Taiwan 5
XK - ???statistics.table.value.countryCode.XK??? 5
HN - Honduras 4
IS - Islanda 4
Totale 59.076
Salva come PNG Salva come JPEG
Città #
Dallas 4.499
Southend 3.025
Dublin 2.948
Singapore 2.270
Fairfield 2.070
Ashburn 1.801
Moscow 1.533
Chandler 1.425
Santa Clara 1.326
Hong Kong 1.026
Beijing 905
Woodbridge 879
Siena 817
Houston 768
Seattle 759
Wilmington 696
Hefei 639
Cambridge 629
Jacksonville 582
Seoul 528
Munich 486
Princeton 473
Milan 449
Helsinki 413
Ann Arbor 405
Los Angeles 404
New York 402
Lastra a Signa 349
Florence 318
Rome 205
Ho Chi Minh City 186
Dong Ket 184
Nanjing 177
São Paulo 176
Boardman 160
Buffalo 154
San Diego 153
Shanghai 151
The Dalles 146
Chicago 145
Dearborn 138
Bengaluru 135
Council Bluffs 132
London 128
San Mateo 127
Turku 123
Málaga 120
Redondo Beach 117
Hanoi 116
Tokyo 116
Fremont 100
Warsaw 100
Nuremberg 96
Abidjan 90
Lappeenranta 89
Düsseldorf 82
Lauterbourg 79
Nanchang 74
Brooklyn 73
Portsmouth 67
Stockholm 67
Brno 66
Montreal 66
Frankfurt am Main 61
Denver 60
Phoenix 59
Johannesburg 57
Rio de Janeiro 56
Washington 56
Menlo Park 55
Toronto 55
Atlanta 54
Chennai 52
Guangzhou 52
Shenyang 52
Vienna 52
Ottawa 50
Poplar 49
San Francisco 46
Columbus 45
Changsha 44
Orem 44
Brussels 42
Catania 42
Boston 41
Gavirate 41
Naples 41
Hangzhou 39
Norwalk 39
Tashkent 39
Belo Horizonte 38
Izmir 38
Mexico City 37
Olomouc 37
Manchester 36
Amsterdam 35
Dhaka 35
Zhengzhou 34
Salt Lake City 33
Tianjin 33
Totale 38.641
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.025
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 546
A first update on mapping the human genetic architecture of COVID-19 541
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 458
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 356
Cytokine modulators in the treatment of sarcoidosis 349
Genetic mechanisms of critical illness in COVID-19 333
Antirheumatic agents in covid-19: is IL-6 the right target? 332
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 331
An explainable model of host genetic interactions linked to COVID-19 severity 327
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 320
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 310
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 307
Peripheral biomarkers' panel for severe COVID-19 patients 292
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 288
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 287
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 283
Pathogen-sugar interactions revealed by universal saturation transfer analysis 274
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 270
Mapping the human genetic architecture of COVID-19 267
Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies 263
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 262
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 262
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 259
POS0871 diagnostic accuracy og power doppler ultrasonography for the diagnosis of idiopathic inflammmatory myopathies 258
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 255
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 253
Exhaled nitric oxide in interstitial lung diseases 252
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 252
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 250
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 248
Gorham-Stout disease management during pregnancy 248
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 247
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 246
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 244
Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways 244
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 243
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 242
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 240
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 237
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 235
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 234
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 234
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 232
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 231
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 229
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 228
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 228
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 227
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 227
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 226
Omalizumab treatment in Samter's triad: case series and review of the literature 225
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 224
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 223
Serum amyloid A in patients with idiopathic pulmonary fibrosis 221
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 220
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 220
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 220
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 220
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline 219
Prognostic bioindicators in severe COVID-19 patients 219
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 218
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 217
Serial KL-6 measurements in COVID-19 patients 215
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 215
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 214
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 212
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 211
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 210
Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer 209
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 209
Chitotriosidase activity in patients with interstitial lung disesaes 208
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 208
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 206
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. 206
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 206
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 205
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 205
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 204
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 204
NK and NKT-like cells in granulomatous and fibrotic lung diseases 203
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 203
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 203
A functional proteomics approach to the comprehension of sarcoidosis 202
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 202
The analysis of tryptase in serum of sarcoidosis patients 201
Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases 201
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 201
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 199
Quality of life, anxiety and depression in Sarcoidosis 198
Phenotypes of organ involvement in sarcoidosis 197
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 197
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 196
Assessment of cardiac involvement in sarcoidosis by echocardiography 194
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 193
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 193
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 193
Proteome analysis of bronchoalveolar lavage in lung diseases 192
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 192
Fibrotic Lung Toxicity Induced by Hydroxycarbamide 191
Totale 25.176
Salva come PNG Salva come JPEG
Categoria #
all - tutte 202.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 202.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.451 0 0 0 0 0 654 316 661 494 375 421 530
2021/20224.498 350 593 368 305 222 157 199 211 185 526 484 898
2022/20235.729 424 592 717 691 415 1.044 359 485 447 202 213 140
2023/20245.524 218 138 517 273 294 1.280 1.644 226 62 179 179 514
2024/202512.165 715 524 1.290 671 1.397 660 611 736 943 617 1.273 2.728
2025/202618.924 2.060 3.922 3.596 3.385 5.267 694 0 0 0 0 0 0
Totale 60.517